Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis
Main Authors: | S Ward, A Scope, R Rafia, A Pandor, S Harnan, P Evans, L Wyld |
---|---|
Format: | Article |
Language: | English |
Published: |
NIHR Journals Library
2013-10-01
|
Series: | Health Technology Assessment |
Online Access: | https://doi.org/10.3310/hta17440 |
Similar Items
-
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis
by: Sue Harnan, et al.
Published: (2019-06-01) -
Cost-utility analysis of adjuvant goserelin (Zoladex) and adjuvant chemotherapy in premenopausal women with breast cancer
by: Cheng Tsui, et al.
Published: (2012-01-01) -
The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation
by: A Pandor, et al.
Published: (2006-11-01) -
Scenarios of cost-savings associated with Oncotype DX® test-guided decisions for adjuvant chemotherapy in early breast cancer in Germany
by: M.P. Lux, et al.
Published: (2021-04-01) -
Rehabilitation Effect of Systematic Exercise on Breast Cancer Patients after Adjuvant Chemotherapy
by: Ling Yan, et al.
Published: (2010-08-01)